• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TLR7 和 IRF7 缺陷的小鼠通过减少干扰素的产生而加重 COVID-19 的严重程度。

Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.

机构信息

Tulane National Primate Research Center, Covington, LA, USA.

Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, LA, USA.

出版信息

Commun Biol. 2024 Sep 17;7(1):1162. doi: 10.1038/s42003-024-06872-5.

DOI:10.1038/s42003-024-06872-5
PMID:39289468
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11408513/
Abstract

Toll-like receptor 7 (Tlr7) deficiency-accelerated severe COVID-19 is associated with reduced production of interferons (IFNs). However, the underlying mechanisms remain elusive. To address these questions, we utilize Tlr7 and Irf7 deficiency mice, single-cell RNA analysis together with bone marrow transplantation approaches. We demonstrate that at the early phase of infection, SARS-CoV-2 causes the upregulation of Tlr7, Irf7, and IFN pathways in the lungs of the infected mice. The deficiency of Tlr7 and Irf7 globally and/or in immune cells in mice increases the severity of COVID-19 via impaired IFN activation in both immune and/or non-immune cells, leading to increased lung viral loads. These effects are associated with reduced IFN alpha and gamma levels in the circulation. The deficiency of Tlr7 tends to cause the reduced production and nuclear translocation of interferon regulatory factor 7 (IRF7) in the lungs of the infected mice, indicative of reduced IRF7 activation. Despite higher amounts of lung viral antigen, Tlr7 or Irf7 deficiency resulted in substantially reduced production of antibodies against SARS-CoV-2, thereby delaying the viral clearance. These results highlight the importance of the activation of TLR7 and IRF7 leading to IFN production on the development of innate and adaptive immunity against COVID-19.

摘要

Toll 样受体 7(Tlr7)缺陷加速严重 COVID-19 与干扰素(IFNs)产生减少有关。然而,其潜在机制仍不清楚。为了解决这些问题,我们利用 Tlr7 和 Irf7 缺陷小鼠、单细胞 RNA 分析以及骨髓移植方法。我们表明,在感染的早期阶段,SARS-CoV-2 导致感染小鼠肺部的 Tlr7、Irf7 和 IFN 途径上调。在小鼠中全身性或免疫细胞中缺乏 Tlr7 和 Irf7 通过在免疫和/或非免疫细胞中 IFN 激活受损,增加 COVID-19 的严重程度,导致肺部病毒载量增加。这些效应与循环中 IFNα和 IFNγ水平降低有关。Tlr7 的缺乏往往导致感染小鼠肺部中干扰素调节因子 7(IRF7)的产生和核易位减少,表明 IRF7 激活减少。尽管肺部病毒抗原含量较高,但 Tlr7 或 Irf7 缺陷导致针对 SARS-CoV-2 的抗体产生大量减少,从而延迟了病毒清除。这些结果强调了 TLR7 和 IRF7 的激活导致 IFN 产生对 COVID-19 固有和适应性免疫发展的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/c6cd80217478/42003_2024_6872_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/5570136161c3/42003_2024_6872_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/01ea1b270f79/42003_2024_6872_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/4baa3a6f65c1/42003_2024_6872_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/c4e7b994f32e/42003_2024_6872_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/4db9460571a9/42003_2024_6872_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/c6cd80217478/42003_2024_6872_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/5570136161c3/42003_2024_6872_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/01ea1b270f79/42003_2024_6872_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/4baa3a6f65c1/42003_2024_6872_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/c4e7b994f32e/42003_2024_6872_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/4db9460571a9/42003_2024_6872_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c523/11408513/c6cd80217478/42003_2024_6872_Fig8_HTML.jpg

相似文献

1
Deficiency of Tlr7 and Irf7 in mice increases the severity of COVID-19 through the reduced interferon production.TLR7 和 IRF7 缺陷的小鼠通过减少干扰素的产生而加重 COVID-19 的严重程度。
Commun Biol. 2024 Sep 17;7(1):1162. doi: 10.1038/s42003-024-06872-5.
2
Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.Toll样受体7(TLR7)介导的抗病毒反应可保护小鼠免受致命的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染。
J Virol. 2025 May 20;99(5):e0166824. doi: 10.1128/jvi.01668-24. Epub 2025 Mar 31.
3
CCR2 Signaling Restricts SARS-CoV-2 Infection.CCR2 信号限制 SARS-CoV-2 感染。
mBio. 2021 Dec 21;12(6):e0274921. doi: 10.1128/mBio.02749-21. Epub 2021 Nov 9.
4
IFN-λ uniquely promotes CD8 T cell immunity against SARS-CoV-2 relative to type I IFN.IFN-λ 相对于 I 型 IFN ,特异性地促进 CD8 T 细胞对 SARS-CoV-2 的免疫应答。
JCI Insight. 2024 May 21;9(13):e171830. doi: 10.1172/jci.insight.171830.
5
Exploring the Contribution of TLR7 to Sex-Based Disparities in Respiratory Syncytial Virus (RSV)-Induced Inflammation and Immunity.探索Toll样受体7(TLR7)在呼吸道合胞病毒(RSV)诱导的炎症和免疫中基于性别的差异所起的作用。
Viruses. 2025 Mar 16;17(3):428. doi: 10.3390/v17030428.
6
Interferon Regulatory Factor 3 Exacerbates the Severity of COVID-19 in Mice.干扰素调节因子3加剧小鼠新冠病毒病的严重程度
Crit Care Explor. 2025 Mar 17;7(3):e1225. doi: 10.1097/CCE.0000000000001225. eCollection 2025 Mar.
7
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.Ⅰ型和Ⅲ型干扰素限制 SARS-CoV-2 感染人呼吸道上皮细胞。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00985-20.
8
Differential immunoregulation by human surfactant protein A variants determines severity of SARS-CoV-2-induced lung disease.人表面活性蛋白A变体的差异性免疫调节决定了SARS-CoV-2诱导的肺部疾病的严重程度。
Front Immunol. 2025 Apr 2;16:1462278. doi: 10.3389/fimmu.2025.1462278. eCollection 2025.
9
Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.严重 COVID-19 模型中对 SARS-CoV-2 感染反应的动力学多组学分析。
J Virol. 2021 Sep 27;95(20):e0101021. doi: 10.1128/JVI.01010-21. Epub 2021 Jul 28.
10
Association Between Single-Nucleotide Polymorphisms in (), , and Genes with Severe Symptoms in Children Presenting COVID-19.新型冠状病毒肺炎患儿中()、、和基因单核苷酸多态性与严重症状之间的关联。 (注:原文括号处内容缺失)
Viruses. 2024 Dec 30;17(1):35. doi: 10.3390/v17010035.

引用本文的文献

1
Ageing and dysregulated lung immune responses in fatal COVID-19.致命性新冠肺炎中的衰老与失调的肺部免疫反应
Immun Ageing. 2025 Jul 17;22(1):32. doi: 10.1186/s12979-025-00525-9.
2
Total, not isoform-specific, Lyn expression by macrophages promotes TLR activation and restricts proliferation.巨噬细胞的Lyn表达总量(而非特定亚型)可促进Toll样受体(TLR)激活并限制增殖。
bioRxiv. 2025 Jul 10:2025.07.07.663098. doi: 10.1101/2025.07.07.663098.
3
TLR7-Adjuvanted Ionizable Lipid Nanoparticles for mRNA Vaccine Delivery.用于mRNA疫苗递送的TLR7佐剂可电离脂质纳米颗粒

本文引用的文献

1
Natural Killer Cells Do Not Attenuate a Mouse-Adapted SARS-CoV-2-Induced Disease in Mice.自然杀伤细胞不会减轻小鼠适应的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)在小鼠中诱导的疾病。
Viruses. 2024 Apr 15;16(4):611. doi: 10.3390/v16040611.
2
COVID-19 and influenza infections mediate distinct pulmonary cellular and transcriptomic changes.COVID-19 和流感感染介导肺部细胞和转录组的不同变化。
Commun Biol. 2023 Dec 13;6(1):1265. doi: 10.1038/s42003-023-05626-z.
3
IRF7: role and regulation in immunity and autoimmunity.IRF7:在免疫和自身免疫中的作用和调节。
AAPS J. 2025 Apr 25;27(4):80. doi: 10.1208/s12248-025-01073-2.
4
Cytosolic nucleic acid sensing as driver of critical illness: mechanisms and advances in therapy.胞质核酸感应作为危重症的驱动因素:机制与治疗进展
Signal Transduct Target Ther. 2025 Mar 19;10(1):90. doi: 10.1038/s41392-025-02174-2.
Front Immunol. 2023 Aug 10;14:1236923. doi: 10.3389/fimmu.2023.1236923. eCollection 2023.
4
B cell-intrinsic TLR7 signaling is required for neutralizing antibody responses to SARS-CoV-2 and pathogen-like COVID-19 vaccines.B细胞内在的TLR7信号传导对于中和针对SARS-CoV-2和病原体样COVID-19疫苗的抗体反应是必需的。
Eur J Immunol. 2023 Oct;53(10):e2350437. doi: 10.1002/eji.202350437. Epub 2023 Jul 12.
5
Interferon regulatory factor 7 in inflammation, cancer and infection.干扰素调节因子 7 在炎症、癌症和感染中的作用。
Front Immunol. 2023 May 12;14:1190841. doi: 10.3389/fimmu.2023.1190841. eCollection 2023.
6
COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies.2023年初的新型冠状病毒肺炎:严重急性呼吸综合征冠状病毒2的结构、复制机制、变体、诊断测试以及疫苗与药物研发研究
MedComm (2020). 2023 Apr 8;4(2):e228. doi: 10.1002/mco2.228. eCollection 2023 Apr.
7
Early Treatment with Pegylated Interferon Lambda for Covid-19.聚乙二醇干扰素 λ 早期治疗 COVID-19。
N Engl J Med. 2023 Feb 9;388(6):518-528. doi: 10.1056/NEJMoa2209760.
8
A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2.TLR7 纳米颗粒佐剂促进针对流感和 SARS-CoV-2 异源株的广泛免疫应答。
Nat Mater. 2023 Mar;22(3):380-390. doi: 10.1038/s41563-022-01464-2. Epub 2023 Jan 30.
9
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学:免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
10
Long COVID: major findings, mechanisms and recommendations.长新冠:主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.